Anti-CD22 CAR-T Cells / Beijing Boren Hospital - LARVOL DELTA

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov) - P2 | N=14 | Completed | Sponsor: Beijing Boren Hospital | Recruiting ➔ Completed | N=100 ➔ 14

Enrollment change • IO biomarker • Trial completion • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD22

FIVE-YEAR OUTCOME OF CD19 COMBINED WITH CD22 CAR-T CELL THERAPY IN B-ALL PATIENTS RELAPSED AFTER ALLO-TRANSPLANTATION (EHA 2024) - "In post-HCT relapsed B-ALL patients who used to have an extremely poorprognosis, our combination treatment of CD19 and CD22 CAR-T cellstremendously improved long-term survival with the 5-year OS of 75% and EFSof 50%, respectively."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Herpes Zoster • Infectious Disease • Leukemia • Oncology • Pediatrics • Respiratory Diseases • Transplantation • CD22

The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. (PubMed, J Oncol) - "For patients with autologous hematopoietic stem cell successful collection, CD19/20/22CAR T-cell immunotherapy following ASCT was performed with the thiotepa-containing conditioning regimen, while sequential CD19/CD20/CD22CAR T-cell therapy was applied. For lymphodepletion, patients received bendamustine or fludarabine monotherapy or fludarabine combined with cyclophosphamide pre-CART-cell infusion...No treatment-related death occurred. The CAR T-cell therapy could augment its efficacy in the treatment of advanced relapsed/refractory CNS B-cell lymphoma, while ASCT in combination with CART can induce durable responses and OS with a manageable side effect."

CAR T-Cell Therapy • Journal • Bone Marrow Transplantation • CNS Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19 • CD20

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Beijing Boren Hospital | Trial completion date: Oct 2022 ➔ Oct 2024 | Trial primary completion date: May 2022 ➔ May 2024

CAR T-Cell Therapy • IO biomarker • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD22

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL. (PubMed, Front Oncol) - "We previously confirmed that sequential infusions of CD20 and CD22 CAR-T cells significantly improved the prognosis of the B-NHL patients, while some advanced patients still progressed to death during these CAR-T cell treatments...Disease progression was observed in both patients after primary CAR-T cell infusion but robust re-expansion of prior CAR-T cells and anti-tumor effects was induced by infusion of a secondary CAR-T cells. These results indicate sequential infusions of CAR-T cells with a short interval may improve therapeutic efficacy in the B-NHL patients by promoting expansion of prior CAR-T cells."

CAR T-Cell Therapy • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20 • CD22

[VIRTUAL] COMBINED TREATMENT OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANSPLANTATION WITH CAR T-CELL THERAPY IMPROVES OUTCOMES IN MANAGEMENT OF ADVANCED RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM B-CELL LYMPHOMA (EHA 2021) - "The ASCT combined with CD19, CD20 or CD22 CAR T-cell therapy would be then administered to patients whose stem cells were successfully collected or had been already prepared...In comparison, in the group of ASCT combined with CAR T-cells therapy, patients in remission had longer PFS (11 months vs 4 months, P=0.02), with no significant difference in the overall survival length between the two groups ( 11 months vs 9 months, P =0.52). Conclusion 1.The CAR T-cell therapy could augment its efficacy in treatment of advanced R/RCNSBL.2.The neurotoxicity of CAR T- cells therapy could be mitigated, and there was no death related to treatment.3.The combined treatment of ASCT and CAR T-cell therapy could increase sustained response and longer survival length."

CAR T-Cell Therapy • Bone Marrow Transplantation • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19 • CD20 • CD22 • MRI

[VIRTUAL] HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CONDITIONING INCLUDING ALLOGENEIC BISPECIFIC CAR-T CELLS TARGETING BOTH CD19 AND CD22 FOR REFRACTORY/RELAPSED B-CELL NON-HODGKIN LYMPHOMA (EHA 2021) - "Conditioning with busulfan, fludarabine-based regimen combined with allo-CD19/CD22 CAR-T was applied. Tacrolimus, mycophenolate mofetil, a short-term methotrexate and antithymocyte globulin were used for graft-versus-host disease (GVHD) prophylaxis...CAR-T cells still exist persistently post-transplant in majority of patients, which may contribute a long-term anti-lymphoma effect. With current protocol, no aGVHD was observed, viral reactivation was mild and encouraging disease control was found. Haplo-HSCT with conditioning including allo-CD19/CD22 CAR-T cells is a safe and effective strategy for r/r B-NHL. Long-term follow-up is needed."

CAR T-Cell Therapy • IO biomarker • Bone Marrow Transplantation • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19 • CD22 • CD34 • TP53

[VIRTUAL] CD22-TAGETED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2021) - "All patients accepted fludarabine and/or cyclophosphamide before infusion. Among 4 NR patients, 3 died of disease progression, and 1 accepted salvage transplantation who had survived for 4.6 months. Conclusion CD22 CAR T-cells was highly effective in inducing remission in adult r/r B-ALL patients,transplantation followed-by CD22-CART allowed CR patients to obtain a remission of 4-39.7months."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Inflammation • Leukemia • Oncology • Transplantation • CD19 • CD22

[VIRTUAL] LONG-TERM FOLLOW-UP OF SEQUENTIAL CD19-22 CAR T-CELL THERAY IN 20 CHILDREN WITH REFRACTORY OR RELAPSED B-ALL (EHA 2021) - "CD19 and CD22 CAR T cells were infused with a median interval of 1.7 (range, 1.1 to 5.2) months...Conclusion Sequential CD19-22 CAR T cell therapy can achieve promising long-term outcome with a 2-year LFS of 60% in pediatric patient with r/r B-ALL without post-CAR transplantation. Early Ig recovery has high risk of relapse."

CAR T-Cell Therapy • Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Inflammation • Leukemia • Oncology • Pediatrics • Transplantation • CD19 • TP53

Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Beijing Boren Hospital

Clinical • IO Biomarker • New P2 trial